BIOLIFE SOLUTIONS INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. OTHER INFORMATION
Checking your notes…
Rule 10b5-1 Trading Arrangements
The following table identifies and provides the material terms of the Rule 10b5-1 trading arrangements (as such term is defined in Item 408 of Regulation S-K) adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors during the quarter ended December 31, 2024.
| Name and Position | Plan Adoption / Termination | Plan Adoption / Termination Date | Expiration Date | Number of Shares Purchased (Sold) / Terminated under Plan |
|---|---|---|---|---|
| Sarah Aebersold, Chief Human Resources Officer | Adoption | December 11, 2024 | December 17, 2025 | (7,324) |
| Amy DuRoss, Lead Director | Adoption | December 13, 2024 | September 12, 2025 | (5,632) |
| Joydeep Goswami, Director | Adoption | December 13, 2024 | December 13, 2025 | (9,000) |
Non-Rule 10b5-1 Trading Arrangements
During the quarter ended December 31, 2024, none of our officers or directors adopted orterminated any non-Rule 10b5-1 trading arrangement (as such term is defined in Item 408 of Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.